Havana, June 25 (RHC)-- The Cuban medication Heberprot-P, used in the treatment of diabetic foot ulcers, has received a license to begin clinical trials in the United States.
Developed by the Havana-based Center for Genetic Engineering and Biotechnology, the injectable medication accelerates the healing process of diabetic foot ulcers, thus significantly reducing the risk of lower limb amputations in over 78 percent of cases.
Dr. Manuel Raíces Pérez-Castañeda, an expert with the center's strategic products department, told reporters that the center's products are currently registered in more than 34 countries, while by 2015 the center had received a total of 1130 patent requests from around the world, 70 percent of which have already been granted in several European and Latin American countries, as well as in Canada, Russia, Japan, Vietnam and the United States.
The only one of its kind in the world, Heberprot-P offers a novel therapeutic solution to a condition which previously lacked effective treatments. This is why it has received the Gold Medal awarded granted by the World Intellectual Property Organization (WIPO).
- Cuba Holds President Donald Trump Responsible for Setback in Bilateral Migratory Relations
- Pope Francisco Returns to Latin America
- Cuban and U.S. Representatives Hold Meeting on Cyber-security and the Fight against Cyber-crimes
- Cuba Celebrates National Science Day
- RHC's Scientific and Medical Report
- RHC's Arts Roundup
- Max: 19729
- yesterday: 4812
- today: 2753
- online: 207
- total: 4218847